A detailed history of Geode Capital Management, LLC transactions in Macrogenics Inc stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,406,876 shares of MGNX stock, worth $4.61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,406,876
Previous 1,415,239 0.59%
Holding current value
$4.61 Million
Previous $6.01 Million 23.05%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$3.0 - $5.55 $25,089 - $46,414
-8,363 Reduced 0.59%
1,406,876 $4.63 Million
Q2 2024

Aug 09, 2024

SELL
$3.31 - $18.51 $55,521 - $310,486
-16,774 Reduced 1.17%
1,415,239 $6.01 Million
Q1 2024

May 13, 2024

BUY
$9.77 - $21.47 $273,022 - $599,979
27,945 Added 1.99%
1,432,013 $21.1 Million
Q4 2023

Feb 13, 2024

BUY
$4.48 - $10.11 $376,624 - $849,927
84,068 Added 6.37%
1,404,068 $13.5 Million
Q3 2023

Nov 13, 2023

BUY
$4.48 - $6.19 $528,568 - $730,320
117,984 Added 9.82%
1,320,000 $6.15 Million
Q2 2023

Aug 11, 2023

BUY
$4.62 - $7.54 $177,038 - $288,932
38,320 Added 3.29%
1,202,016 $6.43 Million
Q1 2023

May 15, 2023

BUY
$4.82 - $7.24 $165,581 - $248,715
34,353 Added 3.04%
1,163,696 $8.34 Million
Q4 2022

Feb 13, 2023

BUY
$3.34 - $6.98 $269,972 - $564,193
80,830 Added 7.71%
1,129,343 $7.58 Million
Q3 2022

Nov 14, 2022

BUY
$3.01 - $5.22 $69,958 - $121,323
23,242 Added 2.27%
1,048,513 $3.63 Million
Q2 2022

Aug 12, 2022

BUY
$2.25 - $9.99 $80,397 - $356,962
35,732 Added 3.61%
1,025,271 $3.02 Million
Q1 2022

May 13, 2022

SELL
$8.12 - $16.9 $237,282 - $493,851
-29,222 Reduced 2.87%
989,539 $8.72 Million
Q4 2021

Feb 11, 2022

SELL
$15.91 - $21.88 $369,812 - $508,578
-23,244 Reduced 2.23%
1,018,761 $16.4 Million
Q3 2021

Nov 12, 2021

SELL
$19.74 - $28.7 $93,686 - $136,210
-4,746 Reduced 0.45%
1,042,005 $21.8 Million
Q2 2021

Aug 13, 2021

BUY
$20.49 - $35.63 $2.04 Million - $3.55 Million
99,700 Added 10.53%
1,046,751 $28.1 Million
Q1 2021

May 12, 2021

BUY
$18.99 - $33.2 $1.18 Million - $2.07 Million
62,382 Added 7.05%
947,051 $30.2 Million
Q4 2020

Feb 12, 2021

BUY
$19.41 - $26.0 $1.93 Million - $2.58 Million
99,300 Added 12.64%
884,669 $20.2 Million
Q3 2020

Nov 13, 2020

BUY
$24.69 - $31.6 $981,748 - $1.26 Million
39,763 Added 5.33%
785,369 $19.8 Million
Q2 2020

Aug 13, 2020

BUY
$5.2 - $29.12 $10,857 - $60,802
2,088 Added 0.28%
745,606 $20.8 Million
Q1 2020

May 14, 2020

BUY
$4.28 - $12.11 $224,768 - $635,968
52,516 Added 7.6%
743,518 $4.33 Million
Q4 2019

Feb 13, 2020

BUY
$7.95 - $12.27 $618,581 - $954,716
77,809 Added 12.69%
691,002 $7.52 Million
Q3 2019

Nov 12, 2019

BUY
$12.44 - $17.48 $187,396 - $263,318
15,064 Added 2.52%
613,193 $7.82 Million
Q2 2019

Aug 14, 2019

BUY
$14.51 - $19.71 $1.31 Million - $1.78 Million
90,465 Added 17.82%
598,129 $10.2 Million
Q1 2019

May 14, 2019

BUY
$11.11 - $25.6 $575,386 - $1.33 Million
51,790 Added 11.36%
507,664 $9.13 Million
Q4 2018

Feb 13, 2019

BUY
$11.75 - $21.42 $461,140 - $840,649
39,246 Added 9.42%
455,874 $5.79 Million
Q3 2018

Nov 13, 2018

BUY
$19.26 - $23.46 $761,270 - $927,279
39,526 Added 10.48%
416,628 $8.93 Million
Q2 2018

Aug 14, 2018

BUY
$19.78 - $24.67 $1.25 Million - $1.56 Million
63,242 Added 20.15%
377,102 $7.79 Million
Q1 2018

May 15, 2018

BUY
$18.89 - $32.46 $296,591 - $509,654
15,701 Added 5.27%
313,860 $7.9 Million
Q4 2017

Feb 13, 2018

BUY
$16.19 - $20.3 $40,021 - $50,181
2,472 Added 0.84%
298,159 $5.67 Million
Q3 2017

Nov 14, 2017

BUY
$15.52 - $18.94 $166,296 - $202,942
10,715 Added 3.76%
295,687 $5.46 Million
Q2 2017

Aug 14, 2017

BUY
N/A
284,972
284,972 $4.99 Million

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $202M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.